Cancer Technology Hub:
From Bench to Bedside
Explore cutting-edge cancer technologies and our CAR-T Technology Transfer Program — bringing advanced cell therapy manufacturing capabilities to hospitals and health systems worldwide.
The Reality Check: Technology Transfer Is Not a Quick Fix
Myth: "Buying a CAR-T manufacturing kit will instantly make our hospital a cell therapy center."
Reality: Technology transfer is a multi-year institutional commitment, not a product purchase. Success requires: sustained patient volume (100+ patients/year for viability), trained personnel retention (high turnover kills programs), ongoing reagent supply chains, regulatory compliance maintenance, and institutional leadership support. Programs that fail typically do so not because of technology gaps, but because of insufficient patient volume, staff turnover, or lack of long-term institutional commitment. This page helps you assess whether your institution is truly ready — not just whether you can afford the equipment.
Complete CAR-T Manufacturing Solutions
We're not just connecting patients to treatment — we're exporting the technology itself. Complete CAR-T cell therapy manufacturing solutions for hospitals, research centers, and national health systems.
Manufacturing Kits
Complete CAR-T manufacturing kits including viral vectors (CD19, CD22, BCMA), closed-system bioreactors, and quality control reagents.
Training & Certification
Comprehensive training programs for your medical and technical staff. On-site training in China/USA + remote support. Certification upon completion.
Equipment & Infrastructure
Complete cleanroom setup, apheresis machines, flow cytometers, cell culture equipment, and cryopreservation systems. Turnkey solutions.
The Technology Transfer Process
Feasibility Assessment
We evaluate your hospital's infrastructure, regulatory environment, and clinical capabilities. Free initial consultation.
Custom Solution Design
Tailored technology package based on your needs: target antigens (CD19, BCMA, etc.), scale (clinical vs. commercial), and budget.
Training & Certification
3-6 month training program for your team. Includes theoretical courses, hands-on lab training, and clinical protocol development.
Equipment Installation & Validation
On-site installation of all equipment. IQ/OQ/PQ validation. Cleanroom certification. Regulatory documentation support.
Ongoing Support & Quality Assurance
Continuous technical support, reagent supply chain management, and quality control monitoring. Annual audits and recertification.
Investment Overview
| Component | Basic Package | Advanced Package | Commercial Scale |
|---|---|---|---|
| Target Antigens | CD19 only | CD19 + BCMA | CD19, CD22, BCMA + Custom |
| Annual Capacity | 50 patients | 200 patients | 1000+ patients |
| Equipment | Basic cleanroom + manual systems | ISO 7 cleanroom + semi-automated | ISO 5 cleanroom + fully automated |
| Training Duration | 3 months | 6 months | 12 months + ongoing |
| Investment Range | $2M - $5M | $8M - $15M | $20M - $50M |
| ROI Timeline | 3-5 years | 2-4 years | 1-3 years |
We partner with international development banks and healthcare investment funds to provide financing solutions. Government-backed loans available for national health systems.
CAR-T Manufacturing Kits & Components
Everything you need to establish a state-of-the-art CAR-T manufacturing facility
Viral Vectors
GMP-grade lentiviral and retroviral vectors for CAR gene delivery. Available for all major target antigens.
Closed-System Bioreactors
Automated cell culture systems that minimize contamination risk and ensure reproducible manufacturing.
- Single-use cassettes (no cross-contamination)
- Real-time monitoring (pH, DO, glucose)
- Scalable from 50mL to 2L
- FDA/EMA compliant
Quality Control Systems
Comprehensive QC reagents and instruments to ensure product safety, purity, and potency.
- Flow cytometry panels (CAR expression, viability)
- Endotoxin testing kits
- Mycoplasma detection
- Potency assays (cytotoxicity, cytokine release)
Cryopreservation & Storage
Long-term cell storage solutions with validated freezing protocols and liquid nitrogen tanks.
- Control-rate freezers
- Liquid nitrogen storage (-196°C)
- 24/7 temperature monitoring
- Backup power systems
Other Cutting-Edge Cancer Technologies
Beyond CAR-T: Explore the full spectrum of advanced cancer technologies transforming oncology
AI-Powered Imaging
Deep learning algorithms that detect cancer earlier and more accurately than human radiologists.
Explore AI Imaging →Liquid Biopsy
Detect 50+ cancer types from a single blood draw. Monitor treatment response in real-time.
Learn About Liquid Biopsy →Robotic Surgery
Minimally invasive surgical systems with sub-millimeter precision and 3D visualization.
Explore Robotic Surgery →mRNA Therapeutics
Personalized cancer vaccines and therapeutic mRNAs targeting tumor-specific neoantigens.
Learn About mRNA →CRISPR Gene Editing
Precise genome editing for next-generation CAR-T cells and direct tumor targeting.
Explore CRISPR →Smart Nanomedicine
Nanoparticle drug delivery systems that target tumors while sparing healthy tissue.
Learn About Nanomedicine →Technology Readiness Assessment
Is your hospital ready for CAR-T technology transfer? Answer these questions for a preliminary assessment.
🔒 Confidential. Reviewed by our technology transfer team within 48 hours.
Technology Transfer Program Outcomes
Real results from institutions that have completed our technology transfer program
Major University Hospital → First CAR-T Center in Region
National Health System → Multi-Site CAR-T Network
Frequently Asked Questions
Common questions about CAR-T technology transfer and manufacturing
❓ "How long does it take to establish a CAR-T manufacturing facility?"
Answer: Typical timeline is 12-24 months from contract signing to first patient treatment. This includes: feasibility assessment (1 month), facility design and construction (6-12 months), equipment installation and validation (3-6 months), staff training (3-6 months), and regulatory approval (varies by country). Accelerated timelines of 9-12 months are possible with existing infrastructure.
❓ "Do we need to have existing cell therapy experience?"
Answer: No. Our program is designed for institutions starting from scratch. We provide comprehensive training for all staff members, from lab technicians to physicians. However, having an established hematology/oncology department with patient volume (100+ patients/year) is strongly recommended for program sustainability.
❓ "What regulatory approvals are needed?"
Answer: Regulatory requirements vary by country. Typically required: facility licensing (GMP certification), clinical trial applications (for novel constructs), product registration (for commercial products), and import/export permits for viral vectors. We provide full regulatory support including documentation preparation, agency meetings, and inspection readiness. Our team has experience with FDA, EMA, NMPA (China), CDSCO (India), and TITCK (Turkey).
❓ "Can we customize the technology package?"
Answer: Absolutely. Every technology transfer package is tailored to your specific needs. You can choose: target antigens (CD19, BCMA, etc.), manufacturing scale (clinical vs. commercial), level of automation, and specific equipment brands. We also support development of proprietary CAR constructs.
Continue Your Research
🤝 For Partners
Complete partnership framework for hospitals and health systems.
Partnership Guide →⚖️ Legal Framework
Our role, liability boundaries, and patient protections.
Read Legal Framework →👨⚕️ Medical Advisors
Cell therapy experts reviewing technology transfer proposals.
Meet the Team →💎 Financial Transparency
Our revenue model, institutional partnerships, and conflicts of interest.
Financial Disclosure →Ready to Bring CAR-T Technology to Your Institution?
Whether you're a hospital, research center, or national health system — we have a solution for you. Let's discuss how we can establish advanced cell therapy capabilities in your region.
Request Technology Transfer Proposal